Esterase response nano-drug as well as preparation method and application thereof

A nano-medicine and drug technology, applied in nano-medicine, nanotechnology, nanotechnology, etc., can solve the problems of poor targeting, toxic and side effects that cannot be ignored, and difficulty in achieving satisfactory therapeutic effects, so as to achieve low toxic and side effects and improve bioavailability , the effect of good clinical application value

Active Publication Date: 2021-06-22
ZHENGZHOU UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, traditional chemotherapeutic drugs have poor targeting, and their toxic and side effects cannot be ignored, making it difficult to achieve a satisfactory therapeutic effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Esterase response nano-drug as well as preparation method and application thereof
  • Esterase response nano-drug as well as preparation method and application thereof
  • Esterase response nano-drug as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] In this example, nanomedicine was prepared by the following method:

[0061] Esterification: (1) Dissolve VGB polypeptide (20mg), 2,4,6-trichlorobenzoyl chloride (60ul), 4-dimethylaminopyridine, and triethylamine in 1ml of dimethylformamide, avoiding Light reaction for 30 minutes to obtain a homogeneous solution;

[0062] (2) Dissolve 8.8 mg of oridonin ORI in 1 ml of dimethylformamide, add it to the homogeneous solution in (1) above, react at room temperature overnight (time 15 hours), TLC tracking monitoring, The reaction is over.

[0063] Purification: (1) Add excess ether, let it stand for 30 minutes, and filter with suction to obtain a yellow crude product;

[0064] (2) Dissolve the yellow solid in the above (1) with isopropanol, recrystallize and purify to obtain the ORI-VGB amphiphilic molecule. The mass spectrum of the ORI-VGB amphiphilic molecule is as follows figure 1 As shown, it can be seen that the amphiphilic molecule was successfully constructed. fig...

Embodiment 2

[0067] The purpose of this example is to determine the changes in the morphology, particle size and potential of the nanomedicine in the esterase solution.

[0068] The nanomedicine obtained in Example 1 was dissolved in 1 ml of pig liver esterase (100 U / ml, PBS buffer) stock solution. Within a specified time interval, mix 20 μL of the incubation solution with 180 μL of acetonitrile to terminate the esterase reaction, centrifuge at 6000 rpm for 5 min, and finally observe the changes in morphology, particle size and potential. The result is as Figure 4 with Figure 5 shown. Figure 4 It is the transmission electron micrograph of the nano-medicine after being treated with esterase for 1 hour; from Figure 4 It can be seen that the nano-medicine has no obvious nano-spherical structure after esterase treatment; Figure 5 It is the particle size potential distribution diagram, after the esterase treatment, the particle size distribution of the nanomedicine changes rapidly from...

Embodiment 3

[0070] The purpose of this example is to verify the in vitro anti-tumor effect of the nanomedicine prepared in Example 1.

[0071] A non-functional VGC polypeptide (CHDQIHNKEQCPGI) in which the sequence of VGB polypeptides was scrambled was used as a control peptide, and ORI was linked with a VGC polypeptide according to the method in Example 1 as a control sample (abbreviated as ORI-VGC-NPs). Wherein, the amino acid sequence of the VGC polypeptide is shown in SEQ ID NO: 2, and its preparation method refers to the preparation of VGB above.

[0072] Firstly, the tumor cells EC109 were divided into 6×10 per well 3 seeded into 96-well plates and allowed to attach overnight. Cells were then treated with serially diluted experimental samples for 24 hours. The cell viability was assessed using the CCK-8 kit, and the results were as follows Image 6 shown. The VGB group had no obvious killing effect on the tumor, and the IC of the ORI and ORI-VGC-NPs treatment groups 50 were 67....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the field of nano-drugs, and relates to an esterase response nano-drug as well as a preparation method and application thereof. The amphipathic molecules are prepared by forming an ester bond by carboxyl at the C terminal of a polypeptide molecule and hydroxyl of a drug. The polypeptide molecules are annular anti-angiogenesis peptide VGB, and the drug is oridonin ORI. The amphiphilic molecules can be self-assembled into a nano-drug in a water-phase solution under a neutral condition. The nano-drug can release VGB and ORI at a tumor part through enzyme specific enzymolysis. The nano-drug provided by the invention has the advantages of simple preparation method, no covalent bond generation in the self-assembly process, no reverse reaction, good biocompatibility, low toxic and side effects and esterase responsiveness, and has high application value and wide application prospect in preparation of nano-drugs applied to tumor resistance.

Description

technical field [0001] The invention belongs to the field of nano-medicine, and relates to an esterase-responsive nano-medicine, a preparation method and application thereof. Background technique [0002] Molecular self-assembly is one of the important means to prepare nanomaterials. As a new type of "bottom-up" strategy, molecular self-assembly is a supplement to the traditional "top-up" strategy. In general, molecular self-assembly can be simply defined as the spontaneous aggregation of molecules into ordered nanostructures, which are usually jointly driven by non-covalent bonds such as ionic bonds, hydrophobic interactions, van der Waals interactions, and hydrogen bonds. Once started, the process of molecular ordering proceeds automatically to a certain end point, and although the energy of the non-covalent interactions involved in self-assembly is much lower than that of covalent bonds, it is sufficient to produce highly organized and stable nanostructures . The use o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/12A61P35/00B82Y5/00B82Y40/00A61K31/352
CPCA61K38/12A61K31/352A61P35/00B82Y5/00B82Y40/00A61K2300/00
Inventor 祁迎秋沈金秀孟小草王卉聂广军
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products